Agree to some extent. Once the Medigate and Phillipines "trials" are done we will know whether ResApDx generates revenue for the customer or not - although they are a lengthy trial - we have learned to wait. But I suspect this will be the bell whether - the trials of all trials that will tell us whether ResApDx can generate income.
Subscription vs. Price per Cough, page-62
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)